Brain cancers remain one of the world’s greatest current health challenges, and at Oncoceutics we have made it our mission to fight with the brave patients, and their families and doctors, to defeat this disease.
Oncoceutics has partnered with several foundations and patient advocate groups, including the “Musella Foundation for Brain Tumor Research and Information”, “Michael Mosier Defeat DIPG Foundation” , “The Cure Starts Now Foundation”, National Brain Tumor Society, Dragon Master Foundation, and The ChadTough Foundation which have financially supported Oncoceutics and our Expanded Access program through donations and venture philanthropy.
Our goal is to make ONC201 available for all patients who are in medical need through FDA approval. The most efficient path towards accomplishing this goal is via conducting clinical trials. Clinical trials that have been launched are listed on clinicaltrials.gov. For patients who cannot enroll in clinical trials but meet certain eligibility criteria access to ONC201 may be available via an Expanded Access Program. This Expanded Access program is made possible with the support of Michael Mosier Defeat DIPG Foundation, Dragon Master Foundation, and The ChadTough Foundation. Dragon Master Foundation’s support includes contributions from Friends of Emily Hood, Mithil Prasad Foundation, Musella Foundation for Brain Tumor Research, National Brain Tumor Society, Storm the Heavens Fund, and Team Cozzi Foundation.